Vivodyne is a biotechnology company that accelerates drug discovery by performing scalable testing on lab-grown three-dimensional human tissues. Its approach integrates human tissue engineering, robotics, and artificial intelligence to generate large volumes of physiologically relevant data during preclinical research, positioning it within the pharmaceutical and drug discovery industries.
The company's core technology is Pipeline V, a platform that creates a preclinical drug development pipeline using lab-grown human organs. A key component of this is the proprietary Data Engine, a system of robotic machines that tests therapeutics on these tissues. According to the company, this system can conduct tests on over 10,000 independent human tissues simultaneously and across more than 20 human organ models, producing a volume of human data that exceeds the combined output of all clinical trials conducted in the United States.
Vivodyne has secured $82 million in total funding, which includes a $40 million Series A round. The company was founded at the University of Pennsylvania and was named the top "Small but Mighty" company on Fast Company's 2022 World's Most Innovative Companies list, a recognition tied to its mission to replace animal testing with ethical and scalable human-tissue-based solutions.
